Alpha Compute Corp

Portage Biotech Inc. is a clinical-stage immuno-oncology company focused on developing first-in-class therapies to address resistance mechanisms to existing checkpoint inhibitors, aiming to improve anti-tumor responses and quality of life for patients with invasive cancers. The company's core business model revolves around sourcing and developing early- to mid-stage treatments, providing funding, strategic business and clinical counsel, shared services, and financial and project management to execute commercially informed development plans. Portage aims to monetize successful drug candidates through licensing, manufacturing and distribution, or outright sale, rather than directly engaging in commercialization ¹. The company's strategy emphasizes portfolio diversification, capital allocation based on risk-adjusted potential, a lean operating base through virtual infrastructure and external relationships, internal development capabilities complemented by external business development, rigorous asset selection, a focus on translational medicine, and early randomized trials testing non-overlapping mechanisms of action ².

Portage Biotech's product and service lines are primarily focused on two platforms: the Adenosine Receptor Antagonist Platform and the Invariant Natural Killer T-cells (iNKT cells) Platform. The Adenosine Receptor Antagonist Platform includes four development candidates: PORT-6 (TT-10), a selective A2A receptor antagonist; PORT-7 (TT-4), a potent and selective A2B receptor antagonist; PORT-8 (TT-53), a fixed-dose dual inhibitor of A2A and A2B receptors; and PORT-9 (TT-3), an A2B gut-restricted antagonist ³. PORT-6 is currently in a Phase 1a clinical trial (ADPORT-601), with enrollment resuming in March 2025 for the final dose escalation cohort ⁴. PORT-7 is preparing for a first-in-human (FIH) dose escalation arm under the ADPORT-601 umbrella trial, subject to funding and regulatory clearance, and has shown promising preclinical efficacy in a murine mesothelioma model ⁵. PORT-8 and PORT-9 are preclinical stage programs with no company-funded development activities planned at this time ⁶. The iNKT cells Platform, managed by the wholly-owned subsidiary iOx Therapeutics Ltd., includes PORT-2 (IMM60), an iNKT cell engager, and PORT-3 (IMM65), a PLGA-nanoparticle formulation of PORT-2 combined with a NY-ESO-1 peptide vaccine ⁷. Development of PORT-2 was deprioritized and its clinical trial closed in January 2024 due to capital constraints, with a Letter of Intent (LOI) signed in December 2024 for its potential acquisition by Immunova LLC ⁸. PORT-3 is being evaluated in an investigator-sponsored study without direct financial support from Portage ⁹. Other investee programs, PORT-4 (Nanolipogel co-formulation Platform) and PORT-5 (STING Agonist Platform), have had their license agreement terminated (PORT-4) or activities scaled back due to liquidity issues (PORT-5) ¹⁰.

For the fiscal year ended March 31, 2025, Portage Biotech reported a net loss of approximately $6.8 million ¹¹. This compares to a net loss of approximately $75.4 million in Fiscal 2024 ¹² and $104.7 million in Fiscal 2023 ¹³. Total operating expenses for Fiscal 2025 were $7.4 million ¹⁴, comprising $3.1 million in research and development (R&D) expenses ¹⁵ and $4.3 million in general and administrative (G&A) expenses ¹⁶. The company's cash and cash equivalents stood at approximately $1.7 million as of March 31, 2025 ¹⁷, with total current liabilities of approximately $1.1 million ¹⁸. The weighted average number of shares outstanding (basic and diluted) for Fiscal 2025 was 1,183 thousand ¹⁹, resulting in a net loss per share (basic and diluted) of $(5.72) ²⁰. The company's total assets were $2.2 million ²¹ and total liabilities were $3.1 million ²² as of March 31, 2025.

Comparing Fiscal 2025 to Fiscal 2024, the net loss decreased by $68.6 million ²³. Operating expenses decreased by $10.8 million, from $18.2 million in Fiscal 2024 to $7.4 million in Fiscal 2025 ²⁴. This reduction was primarily driven by a $9.4 million decrease in R&D expenses, from $12.5 million in Fiscal 2024 to $3.1 million in Fiscal 2025 ²⁵, mainly due to reduced clinical trial costs and manufacturing-related costs following the pause of sponsored clinical trials ²⁶. G&A expenses also decreased by $1.4 million, from $5.7 million in Fiscal 2024 to $4.3 million in Fiscal 2025 ²⁷, attributed to lower non-cash share-based compensation, professional fees, and directors' fees ²⁸. Notable non-cash items in Fiscal 2024 included an impairment loss of $57.9 million for iOx IPR&D ²⁹, $23.6 million for Tarus IPR&D ³⁰, and $1.0 million for Stimunity ³¹, which were not present in Fiscal 2025 ³².

During Fiscal 2025, Portage made several operational adjustments. In January 2024, prior to the start of Fiscal 2025, the company deprioritized the iNKT program and closed its clinical trial (PORT-2) ³³. In December 2024, an LOI was announced with Immunova LLC for the potential acquisition of iOx Therapeutics Ltd. ³⁴. In January 2025, Tarus Therapeutics, LLC was relaunched as an independently managed company, Cyncado Therapeutics™, to secure external financing and advance its adenosine receptor antagonist portfolio ³⁵. Patient enrollment in the final dose escalation cohort of PORT-6 (ADPORT-601 Phase 1a trial) resumed in March 2025, following a temporary pause in August 2024 ³⁶. Confirmatory preclinical results for PORT-7 in a murine mesothelioma model were announced in April 2025, supporting its advancement ³⁷. The license agreement for PORT-4 (Nanolipogel Co-Formulations) with Yale Ventures was terminated on June 27, 2024 ³⁸. The company also completed a private placement on January 29, 2025, selling 524,390 ordinary shares for aggregate proceeds of $2,150,000 to two directors ³⁹. A 1-for-20 reverse share split was effected on August 15, 2024, to comply with Nasdaq's minimum bid price requirement ⁴⁰.

Portage Biotech's immediate outlook is heavily influenced by its ongoing evaluation of strategic alternatives, which may include partnerships, asset sales, mergers, restructurings (in or out of court), company wind-downs, or new financing transactions ⁴¹. The company explicitly states that its current cash and cash equivalents of $0.6 million as of July 21, 2025, combined with potential proceeds of up to $3,377,250 from an "at-the-market" (ATM) sales agreement with Rodman & Renshaw LLC, would not be sufficient to satisfy anticipated operating and other funding requirements for the next twelve months ⁴². This raises significant doubt about the company's ability to continue as a going concern ⁴³. The description of future activities assumes the availability of additional capital to support ongoing and future clinical development ⁴⁴.

A key growth area for Portage is the advancement of its Adenosine Receptor Antagonist Platform, particularly PORT-6 and PORT-7. Patient enrollment in the final dose escalation cohort of PORT-6 (A2A antagonist) under the Phase 1a ADPORT-601 clinical trial resumed in March 2025, driven by favorable safety and preliminary activity signals ⁴⁵. Following the completion of this PORT-6 cohort, Portage plans to evaluate the advancement of the PORT-7 monotherapy and PORT-6 + PORT-7 combination arms within the ADPORT-601 trial ⁴⁶. PORT-7 (A2B antagonist) has demonstrated promising preclinical efficacy data in a murine mesothelioma model, showing anti-tumor activity as monotherapy and in combination with anti-PD-1 checkpoint blockade ⁴⁷. The company is advancing plans to co-administer PORT-6 and PORT-7 as a dual-receptor adenosine blockade strategy to enhance anti-tumor immune responses in advanced solid tumors, though the initiation and execution of this strategy are subject to available funding and operational readiness ⁴⁸. The relaunch of Tarus Therapeutics, LLC as Cyncado Therapeutics™ in January 2025, with Peter Molloy appointed CEO, is specifically aimed at securing external financing to advance PORT-6, PORT-7, PORT-8, and PORT-9 ⁴⁹.

Operationally, the company has significantly scaled back its research and development activities due to funding constraints. R&D expenses decreased by approximately $9.4 million, or 75%, from $12.5 million in Fiscal 2024 to $3.1 million in Fiscal 2025 ⁵⁰, primarily due to reduced clinical trial and manufacturing costs ⁵¹. The company maintains a lean operating base through a virtual infrastructure and external relationships, partnering with service providers rather than incurring capital-intensive lab, manufacturing, and equipment expenditures ⁵². The clinical service agreement with a third-party provider for Tarus has been extended to the earlier of February 20, 2026, or completion of services, with budgeted costs of approximately $6.9 million (reduced from $12.1 million) ⁵³.

Regarding capital allocation, the company will require significant additional capital to execute its longer-term business plan and fund product development, clinical trials, regulatory approvals, intellectual property safeguarding, and potential commercialization efforts ⁵⁴. Historically, operations have been funded by equity and, to a lesser extent, debt securities ⁵⁵. On January 29, 2025, Portage completed a private placement, selling 524,390 ordinary shares for aggregate proceeds of $2,150,000 to two directors, with proceeds intended for general corporate purposes and working capital ⁵⁶. On June 5, 2025, the company issued 625,000 ordinary shares for $5,000,000 in exchange for 1,165,501 shares of Compedica Holdings Limited, with the agreement stating that for 12 months from the subscription date, Portage will use not less than 50% of net funds from any equity funding arrangement to subscribe for new Compedica equity at $4.29 per share, to support Compedica's device development and commercialization ⁵⁷.

Management has explicitly flagged structural headwinds and execution risks. The company has limited funding and may have to pause aspects of its development efforts, as it did in 2024 ⁵⁸. There is no assurance that the evaluation of strategic alternatives will result in any agreements or transactions, or that any completed transactions will be successful or on attractive terms ⁵⁹. The process of reviewing strategic alternatives may incur additional costs, negatively impact the ability to attract and retain key employees, and expose the company to potential litigation ⁶⁰. The company has a history of operating losses and may never achieve profitability ⁶¹. The ability to generate revenue is largely dependent on developing new drug candidates and partnering with major pharmaceutical companies for commercialization, which is a lengthy and resource-intensive process ⁶². Clinical trials are expensive, time-consuming, and their outcomes are uncertain, with a high rate of attrition for product candidates ⁶³. Difficulties in patient enrollment, unforeseen safety issues, or lack of demonstrated efficacy could delay or terminate trials ⁶⁴. Reliance on third parties for manufacturing preclinical and clinical drug supplies, and for commercial production, poses risks related to production yields, quality control, regulatory compliance, and costs ⁶⁵. Government actions on tariffs, trade policies, immigration, and research grants may impede research and capital raising efforts ⁶⁶.

Portage Biotech faces material risks, primarily stemming from its precarious financial position and the inherent uncertainties of pharmaceutical development. The company's cash and cash equivalents of $0.6 million as of July 21, 2025, combined with potential ATM proceeds of up to $3,377,250, are explicitly stated as insufficient to meet anticipated operating and funding requirements for the next twelve months, raising significant doubt about its ability to continue as a going concern ⁶⁷. This liquidity risk is exacerbated by a history of operating losses and the substantial capital required for clinical trials, regulatory approvals, and commercialization, with no assurance of obtaining necessary funds on acceptable terms ⁶⁸. Operational risks include the high rate of attrition in clinical development, potential delays or failures in trials due to patient enrollment difficulties, safety issues, or lack of efficacy, and reliance on third-party manufacturers for cGMP compliance ⁶⁹. Competitive risks arise from the rapidly changing medical technology within the life sciences industry, which could render product candidates obsolete ⁷⁰. Regulatory risks include the extensive and uncertain process of obtaining regulatory approvals, as well as potential changes in U.K. and EU regulatory frameworks due to Brexit, which could increase costs and affect operations ⁷¹. Geopolitical and macroeconomic risks include foreign exchange fluctuations, capital controls, political instability, and the impact of economic uncertainty, inflation, and changes in U.S. tariff and import/export regulations on business activities and capital raising ⁷². The company also faces risks related to maintaining intellectual property protection, successfully integrating acquisitions, and potential cybersecurity incidents or data breaches ⁷³.

Management's message to shareholders conveys a tone of strategic realignment and cautious optimism, tempered by significant financial constraints. They emphasize the strategic adjustments made to clinical development programs during Fiscal 2025, including the deprioritization of the iNKT program and the temporary pause in enrollment for the PORT-6 arm of the ADPORT-601 trial, both driven by capital constraints and the broader funding environment ⁷⁴. Despite these challenges, management highlights the resumption of PORT-6 enrollment in March 2025, supported by a favorable safety profile and preliminary signs of clinical activity, and promising preclinical data for PORT-7 in mesothelioma ⁷⁵. A key strategic priority is the relaunch of Tarus Therapeutics, LLC as Cyncado Therapeutics™ in January 2025, with a new CEO, Peter Molloy, specifically tasked with securing external financing to advance the adenosine receptor antagonist portfolio ⁷⁶. Management also stresses the ongoing evaluation of a broad set of strategic alternatives, including partnerships, asset sales, mergers, restructurings, company wind-downs, or new financing transactions, to address the critical need for additional capital ⁷⁷. They explicitly state that current cash and cash equivalents of $0.6 million as of July 21, 2025, plus potential ATM proceeds of up to $3,377,250, would not be sufficient to satisfy anticipated operating and other funding requirements for the next twelve months ⁷⁸, underscoring the urgency of their financing efforts.